OR WAIT 15 SECS
PlantForm and PharmaPraxis announce plans to develop six biopharmaceutical targets for the Brazilian market.
PlantForm and PharmaPraxis announce plans to developm six biopharmaceutical targets for the Brazilian market.
PlantForm Corporation of Canada and PharmaPraxis of Brazil have announced a joint venture to develop, manufacture and commercialize biosimilar and/or biobetter versions of six biopharmaceuticals for the Brazilian market, using PlantForm’s manufacturing system.
The joint venture will first develop a biosimilar/biobetter version of the oncology drug Avastin (bevacizumab), in collaboration with the Fraunhofer Center for Molecular Biology in Newark, Del., which will produce the active pharmaceutical ingredient (API) for clinical trials.
Brazilian government corporation Bio-Manguinhos will also participate in the project. Bio-Manguinhos is responsible for technology development and production of vaccines, reagents and biopharmaceuticals to meet public health demands.
The joint venture will build a pilot cGMP biopharmaceutical manufacturing facility in Brazil.